Venetoclax

Overview

ABT-199 is an anti-apoptotic protein Bcl-2 inhibitor that mimics BH3-only proteins, the native ligands of Bcl-2 and programmed cell death activators, repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.

SparkCures ID 24
Developed By AbbVie
Generic Name Venetoclax
Additional Names ABT-199
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
CANOVA
View Trial
Verified
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
View Trial
Verified
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple ...
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies
View Trial
Myeloma-Developing Regimens Using Genomics
MYDRUG
View Trial
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
CANOVA
View Trial
Verified
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)
View Trial
Verified
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple ...
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies
View Trial
Myeloma-Developing Regimens Using Genomics
MYDRUG
View Trial
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Phase III BELLINI: Updated Results With Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

May 31, 2020

  • Venetoclax added to Vd significantly improved PFS, ORR, and MRD negative rates in patients with R/R multiple myeloma but was associated with worse OS outcomes
  • Increased incidence of deaths attributed to infections
  • (11;14) cytogenetic marker associated with favorable risk-benefit profile for survival outcomes with venetoclax + Vd combination
  • Investigators conclude that the results support a t(11;14) biomarker-driven approach for venetoclax development in R/R multiple myeloma
Read More

Resources

Phase III Study With Venetoclax Combo Identifies New Biomarker for Relapsed/Refractory Myeloma

December 11, 2019

The phase III BELLINI trial (NCT02755597) demonstrated translocation(t)(11;14) and high BCL2 gene expression are predictive of response to treatment with the addition of venetoclax (Venclexta) to bortezomib (Velcade) plus dexamethasone in patients with relapsed/refractory multiple myeloma, according to the findings presented at the 2019 American Society of Hematology (ASH) Annual Meeting.
Read More
Partial Clinical Hold Lifted for One Venetoclax Trial in Multiple Myeloma

June 24, 2019

Read More
ASCO 2019: Venetoclax Updates with Mike Thompson, MD, PhD, Advocate Aurora Health

June 18, 2019

Read More
The Confounding Case of Venetoclax in Multiple Myeloma

May 16, 2019

Read More
FDA Halts Enrollment on Venetoclax Myeloma Trials

March 19, 2019

Read More
Genetech Patient Foundation

Living with a serious illness can come with many challenges. Getting Genentech medicines shouldn’t be one of them.

The Genentech Patient Foundation gives free Genentech medicine to people who don’t have insurance coverage or who have financial concerns.

Learn More